The programme will combine Magellan’s clinical support as well as evidence-based resources with digital health company Neuroflow’s cloud-based platform and its engagement approach.
It will offer recommendations to participating members of Magellan using the NeuroFlow app or website, starting 1 January 2021.
The members will also gain access to activities intended to improve their health, including evidence-based videos, articles and behavioural trackers.
In addition, they will be able to utilise Magellan’s digital cognitive behavioural therapy programmes (DCBTs), MoodCalmer for depression and FearFighter for anxiety.
These activities will offer participants customised, self-directed behavioural health resources, tools and support via NeuroFlow’s app and website.
Magellan Healthcare commercial behavioural health senior vice-president and general manager Jeff Bringardner said: “Magellan Healthcare has offered DCBTs recognised by the Substance Abuse and Mental Health Services Administration (SAMHSA) for many years. This collaboration with NeuroFlow enables us to offer members a seamless wellbeing solution.
“We are excited to put our clinical expertise in the palms of our members’ hands and meet them where they are in their healthcare journey.”
According to data from NeuroFlow, 80% individuals go through an initial assessment and 61% use the programme during the first month with 78% users reporting a reduction in symptoms.
Magellan’s offerings also claim to offer similar results, with 57% users reporting less fear and panic, and 80% reporting better sleep.
NeuroFlow CEO Chris Molaro said: “The possibility of a lifetime of improved mental health awareness can start with a single assessment, and we’re proud to collaborate with Magellan on a solution that empowers users to take an active role in their wellness.
“This new programme enables a measurement-based approach to care and provides the right and relevant resources and content based on individual experiences.”